• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Digital Health Alert: 3 New China Regulatory Guidelines Released

Digital Health Alert: 3 New China Regulatory Guidelines Released

Friday, 25 March 2022 / Published in Medical Device, News, NMPA Registration in China

Digital Health Alert: 3 New China Regulatory Guidelines Released

On March 9, 2022, the CMDE (Center for Medical Device Evaluation) of the NMPA (National Medical Products Administration) issued the following 3 regulatory guidelines concerning digital health:

Technical review guideline for the registration of medical device software (No.9-2022)

Scope

Class II and III SaMD (Software as Medical Device) or SiMD (Software in Medical Device)

NMPA Registration of Importing Medical Device Software

The dossier submission should include, but not limited to the following:

  • Marketing approval certificate granted from the product’s country of origin and any related supporting materials.
  • Previous batch of product information submitted before the product-specific change in its country of origin, if any.
  • List out any cultural differences such as the differences in language, functionality, scope of application, etc.

Technical review guideline for the registration of artifical intelligence medical device software (No.8-2022)

Scope

Class Class II and III AI-based SaMD or AI-based SiMD

NMPA Registration of Importing AI Medical Device Software

Based on the intended use, use scenarios, and core functions of the product, the applicant should carry out risk management activities to ensure the risks, such as the differences between Chinese and foreigners in terms of ethnicity, epidemiological characteristics, clinical diagnosis and treatment norms, etc., have been reduced to an acceptable level throughout the whole product lifecycle.

Technical review guideline for the registration of medical device software for cyber security (No.7-2022)

Scope

Class II and III SaMD or SiMD with any of the following three functions:

  • Electronic data interchange
  • Remote access control
  • User access control

Cross-Border Medical Data Transfers

Important data, personal information and human genetic resource information collected and generated in China must be stored in China by law. If there is a business need to share these data to outside of China, security assessment should be carried out in accordance to the requirements and measures formulated by the Cyberspace Administration of China (CAC) in conjunction with relevant departments of the State Council.

By Julie Zhang and Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: AI, AI medical devices, Cyber Security, SaMD, Software, Software as Medical Device, Software in Medical Device

What you can read next

Latest Technical Review Guidelines Issued / Updated
Product Technical Requirements
New Clinical Trial Exemption List for Medical Devices and IVD Reagents
China – Updates for voluntary product safety certification (instead CCC)

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...
  • China medical device quality safety responsibility

    China medical device quality and safety responsibility regulations come into force on March 1, 2023

    China medical device quality and safety respons...
  • China drug standards draft measures

    China drug standards draft measures have been published by the NMPA

    China drug standards draft measures have recent...
  • China special equipment safety supervision

    China special equipment safety supervision – draft provisions released

    China special equipment safety supervision regu...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.